Tempest Therapeutics to Unveil New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma.
Clinical-stage Biotechnology Company Reveals New Data From Amezalpat Study
Clinical-stage Biotechnology Company Reveals…
Clinical-stage Biotechnology Company Reveals New Data From Amezalpat Study
Tempest Therapeutics to Unveil New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma.